ReviewPharmacological research2020
Current targeted therapeutics against COVID-19: Based on first-line experience in China.
Review in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.Immunity, inflammation and disease · 2021Pooled it
- Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.Clinical therapeutics · 2021Trial
- Trial
- Neurological disorders of COVID-19: insights to applications of natural products from plants and microorganisms.Archives of pharmacal research · 2022Review
- Glucocorticoids and COVID-19.Pharmacological research · 2022Review
- Effects of the COVID-19 pandemic on perinatal mental health in Spain: Positive and negative outcomes.Women and birth : journal of the Australian College of Midwives · 2022Article
- Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.Chinese journal of natural medicines · 2021Article
- Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.SLAS discovery : advancing life sciences R & D · 2021Review
- Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.CPT: pharmacometrics & systems pharmacology · 2021Article
- Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.Topics in current chemistry (Cham) · 2021Review
- Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.Frontiers in pharmacology · 2021Review
- Review
- A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.SLAS discovery : advancing life sciences R & D · 2020Review
- Pharmacological treatments of COVID-19.Pharmacological reports : PR · 2020Review
- Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network.Transfusion · 2020Article
- Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions.medRxiv : the preprint server for health sciences · 2020Article
- Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 is a novel strain, causing a global pandemic since the end of 2019. The majority of patients showed nonspecific symptoms such as fever, dry cough, and fatigue. Most patients have a good prognosis while some with severe conditions could rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and even die. The exacerbation of the patient's condition may be due to a cytokine storm in the body. Effective targeted therapies including antiviral and immunization are urgently needed. Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently. We summarize the current therapeutic medicines used in the clinic, hope to be able to provide some implications for clinical medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.